Back to top
more

Nivalis Therapeutics, Inc. (ALPN)

(Delayed Data from NSDQ)

$6.24 USD

6.24
7,474

-0.08 (-1.27%)

Updated May 3, 2019 03:59 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

NA Value NA Growth NA Momentum NA VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

NA

Industry: NA

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Alpine (ALPN) Down on FDA Partial Clinical Hold on Cancer Study

by Zacks Equity Research

The FDA places a partial clinical hold on Alpine's (ALPN) NEON-2 study evaluating the combo of davoceticept plus Merck's Keytruda for treating advanced malignancies. Shares fall.

Minerva Neurosciences (NERV) Reports Q4 Loss, Misses Revenue Estimates

by Zacks Equity Research

Minerva Neurosciences (NERV) delivered earnings and revenue surprises of 40% and 100%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Esperion Therapeutics (ESPR) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Esperion Therapeutics (ESPR) delivered earnings and revenue surprises of 23.71% and 6.21%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Alpine Immune Sciences, Inc. (ALPN) Earnings Expected to Grow: What to Know Ahead of Q3 Release

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Indrajit Bandyopadhyay headshot

3 Small Biotech Stocks in Focus on World Arthritis Day

by Indrajit Bandyopadhyay

Here we discuss three drugs or biotech companies with promising candidates in their pipeline for Arthritis indications.

Alpine Immune Sciences, Inc. (ALPN) Surges 6.2%: Is This an Indication of Further Gains?

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Alpine Immune Sciences, Inc. (ALPN) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -58.62% and 9.15%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Will Alpine Immune Sciences, Inc. (ALPN) Report Negative Q2 Earnings? What You Should Know

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Alpine (ALPN) Enters Immuno-Oncology Collaboration With Merck

by Zacks Equity Research

Alpine (ALPN) signs a collaboration and supply deal with Merck to evaluate ALPN-202 in combination with the latter's Keytruda for treating various types of cancer.

Alpine Immune Sciences, Inc. (ALPN) Moves 9.5% Higher: Will This Strength Last?

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock suggests that there could be more strength down the road.

Alpine Immune Sciences, Inc. (ALPN) Reports Q1 Loss, Lags Revenue Estimates

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of -40.63% and -45.14%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

Earnings Preview: Alpine Immune Sciences, Inc. (ALPN) Q1 Earnings Expected to Decline

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Is the Options Market Predicting a Spike in Alpine (ALPN) Stock?

by Zacks Equity Research

Investors need to pay close attention to Alpine (ALPN) stock based on the movements in the options market lately.

Alpine Immune Sciences, Inc. (ALPN) Reports Q4 Loss, Tops Revenue Estimates

by Zacks Equity Research

Alpine Immune Sciences, Inc. (ALPN) delivered earnings and revenue surprises of 0.00% and 101.39%, respectively, for the quarter ended December 2020. Do the numbers hold clues to what lies ahead for the stock?

Alpine (ALPN) Looks Good: Stock Adds 7.8% in Session

by Zacks Equity Research

Alpine (ALPN) saw a big move last session, as its shares jumped nearly 8% on the day, amid huge volumes.

New Strong Sell Stocks for September 8th

by Zacks Equity Research

Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today.

United Therapeutics (UTHR) Q2 Earnings In Line, Sales Beat

by Zacks Equity Research

United Therapeutics' (UTHR) second-quarter sales beat estimates. Higher sales of Orenitram and Tyvaso offset lower sales of Remodulin and Adcirca.

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

by Zacks Equity Research

The Zacks Analyst Blog Highlights: Alpine Immune Sciences, Actinium Pharmaceuticals, Pacira BioSciences and Translate Bio

Alpine Immune Sciences, Inc. (ALPN) Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences, Inc. (ALPN).

4 Small Drug Stocks Worth Betting on Amid Coronavirus Woes

by Zacks Equity Research

Here we discuss four small stocks from the drug sector, which hold potential for a good run amid the coronavirus crisis.

Alpine Begins Dosing in Phase I Study for Advanced Malignancies

by Zacks Equity Research

Alpine (ALPN) doses the first patient in the phase I NEON-1 study evaluating its pipeline candidate ALPN-202 for treating patients with advanced malignancies.

Translate Bio Up on Vaccine Agreement Expansion With Sanofi

by Zacks Equity Research

Translate Bio (TBIO) and Sanofi expand their tie-up to develop mRNA vaccines for infectious diseases. The deal boosts the company's cash resources significantly along with potential future revenues.

Alpine Skyrockets on License Deal With AbbVie for ALPN-101

by Zacks Equity Research

Alpine (ALPN) signs an agreement with AbbVie granting exclusive worldwide option and license to its pipeline candidate, ALPN-101. The deal significantly boosts Alpine's funds.

Company News for Jun 19, 2020

by Zacks Equity Research

Companies in the news are: SPOT, ALPN, AESE, NEON

Alpine Immune Sciences' Shares March Higher, Can It Continue?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor in Alpine Immune Sciences.